Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies

doi:10.3748/wjg.v11.i28.4300

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 28

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2631)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-6) series.

Item

Count

PDF

298

HTML

2033

Tables (1-6)

300

Sum=2631

Jul 28, 2005 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. Jul 28, 2005; 11(28): 4300-4304
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4300

Table 1 Clinical characteristics of stage IV gastrointestinal cancer

linical characteristics	Gastric cancer		Colorectal cancer
linical characteristics	X group	C group	X group	C group
ale/female	21/11	17/12	19/16	23/12
ge: mean (range/yr)	63.6 (3683)	61.0 (3380)	62.9 (4575)	60.8 (3474)
ecurrence (%)	14 (43.8)	14 (48.3)	8 (22.9)	9 (25.7)
etastasis
iver (%)	17 (53.1)	16 (55.2)	21 (60.0)	22 (62.9)
ung (%)	8 (25.0)	7 (24.1)	11 (31.4)	10 (28.6)
eliac lymph node (%)	21 (65.6)	21 (72.4)	14 (40.0)	15 (42.9)
thers (%)	8 (25.0)	9 (31.0)	12 (34.3)	10 (28.6)
revious chemotherapy	23 (71.9)	22 (75.9)	17 (48.6)	19 (54.3)

Table 2 Different chemotherapeutic effect of gastrointestinal cancers

Therapeutic effect	Gastric cancer		Colorectal cancer		Total
Therapeutic effect	X group	C group	X group	C group	X group	C group
n	24	25	31	34	55	59
CR (n)	1	1	1	0	2	1
PR (n)	13	10	14	14	27	24
NC (n)	5	10	12	14	17	24
PD (n)	5	4	4	6	9	10
CR+PR (n)	14	11	17	14	29	25
(%)	58.3	44.0	54.8	41.2	52.7	42.4
TTP (mo)	7.0±1.3^a	5.4±0.9	7.8±1.9^a	6.7±2.0	7.4±1.7^a	6.0±1.5
1-yr survival (%)	41.7a	36.0	64.5a	52.9	53.1a	44.5

^aP<0.05 vs C group.

Table 3 Chemotherapeutic side effects of gastrointestinal cancers (n)

Side effects	X group (n = 55)				C group (n = 59)
Side effects	I	II	III	IV	I	II	III	IV
Leukopenia	21	8	5	0	20	8	4	0
Thrombocytopenia	10	5	1	0	13	4	2	0
Nausea	15	19	10	2	16	20	11	2
Vomiting	11	11	4	1	14	12	3	2
Diarrhea	7	9	3	0	5	6	2	0
HFS	32	2	1	0	8	2	0	0
Neurotoxicity	12	11	0	0	14	12	1	0

Table 4 Chemotherapeutic DI of gastrointestinal cancers, mg/(m²×wk)

DI	X group			C group
DI	Oxal¹	DDP¹	Xeloda	Oxal¹	DDP¹	CF	5-FU
Standard	43.3	40.0	9 333.3	43.3	40.0	333.3	1 000.0
Actual	40.7	38.3	8 662.7	41.3	38.7	322.7	966.7
Relative	0.94	0.96	0.93	0.95	0.97	0.97	0.97

¹Oxal oxaliplatin; DDP cisplatin.

Table 5 The average cost per patient of two groups (mean±SD, ￥, US $)

Group	Hospitalization(d)	Cost of drug		Other cost		Total cost
Group	Hospitalization(d)	￥	US $	￥	US $	￥	US $
X	5.94±3.11a	7887.33±140.92a	950.28±16.98a	1250.02±101.43a	150.60±12.22a	9137.35±121.18	1100.89±14.60
C	9.37±2.73	6108.97±205.44	736.02±24.75	2 852.75±217.73	343.70±26.23	8961.72±211.59	1 079.73±25.50

^aP<0.05 vs C group.

Table 6 Comparison of cost-effectiveness of two groups

Group	Costs/efficient		Costs/TTP		Costs/1-year survival
Group	￥	US $	￥	US $	￥	US $
X	161.44±2.14^a	19.45±0.26^a	1243.18±16.49^a	149.78±1.99^a	172.24±2.28^a	20.75±0.27^a
C	210.37±4.97	25.35±0.60 1	506.17±35.56	181.47±4.28	201.61±4.76	24.29±0.57

^aP<0.05 vs C group.

Citation: Fan L, Liu WC, Zhang YJ, Ren J, Pan BR, Liu DH, Chen Y, Yu ZC. Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies. World J Gastroenterol 2005; 11(28): 4300-4304
URL: https://www.wjgnet.com/1007-9327/full/v11/i28/4300.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i28.4300